Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...

The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...

Dyne Therapeutics reports positive long-term data for DYNE-251 in Duchenne muscular dystrophy, aiming for U.S. accelerated approval in 2026. Dyne Therapeutics announced new long-term clinical data ...

announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Scotiabank initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm thinks the stock pullback on ...

Furthermore, in DMD, we expect data from the ongoing DELIVER trial of DYNE-251 in late 2025 to support a potential submission for U.S. Accelerated Approval in early 2026, giving us the ...

Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...